SetPoint Medical, a company developing innovative therapies for chronic autoimmune diseases, has secured $140 million in private financing, consisting of the final $25 million tranche of its Series C funding and a $115 million Series D round co-led by Elevage Medical Technologies and Ally Bridge Group. The capital will fuel the commercialization of the SetPoint System, a groundbreaking neuroimmune modulation therapy designed for adults with moderate-to-severe rheumatoid arthritis (RA), while also advancing the company’s pipeline for other autoimmune conditions.
The SetPoint System represents a novel approach to RA treatment by using targeted electrical stimulation of the vagus nerve to modulate the body’s inflammatory response, offering the potential to significantly improve the lives of patients living with chronic autoimmune diseases. The successful commercialization of this technology could also pave the way for addressing other autoimmune disorders in the future.
In preparation for its commercial launch, SetPoint Medical has made two key leadership appointments: Erik Styacich, former Vice President of Sales at Valencia Technologies, joins as Vice President of Sales, and Spencer Bailey, who brings extensive expertise in market access and reimbursement from leadership roles at neuromodulation companies including MicroTransponder, Inc., becomes Vice President of Market Access & Reimbursement.
CEO Murthy V. Simhambhatla, Ph.D., emphasized that these milestones reflect the company’s commitment to a successful and seamless market introduction of the SetPoint System in select U.S. markets later this year, with plans for broader national expansion in 2026, and expressed enthusiasm for welcoming an outstanding group of new investors to its syndicate.
Click here to read the original news story.